Please note

The offer on this page is aimed exclusively at business customers.


Benefits at a glance

  • Day 1 launch possible 
  • Supply from a white spot country
  • All strengths available

Product details


Relapsed and refractory multiple myeloma


1 mg + 2 mg + 3 mg + 4 mg

Dosage form







648 Mio. € (IQVIA 2021 – EU)


  • Development Kick-off
  • Formulation Development
  • Prototype
  • Pilot BE
  • Scale Up
  • Pivotal BE
  • 6 M Stability
  • Dossier
  • EU-Approval


With our Pomalidomide-Dossier, which includes the full range of available strengths, we offer a dossier with a patent pending formulation, backed-up by a reliable supply chain out of a white spot country.

Zone IVb stability data have been generated which allows to supply the product to a wide range of countries.

With Multiple Myeloma being responsible for approximately 1 % of all cancer diagnosis, our product cannot only help a large number of people get adequate access to an effective treatment, but also can unlock a large market potential with significant growth rates of more than 25 % year over year.


Your Contact

Heike Sagi

Heike Sagi

Business Development & Licensing
Senior Director

Midas Pharma GmbH
Rheinstraße 49
55218 Ingelheim
Send E-Mail
  • Disclaimer

    The exploitation, including the development, sale and offer for sale of products and related processes is performed by Midas only in those territories where permissible by applicable patent law in particular, but not limited to EC Directive 2001/83 EC, Article 10, as amended by EC Directive 2004/27 EC. This document, therefore, does not and shall not constitute an offer for sale for the product in territories where an offer for sale or sale is not permissible by law. Midas expressly disclaims any liability for the information provided in this document as well as for damages resulting from or arising out of the use of the product and related process for purposes other than research and development in compliance with applicable laws.


Share this page